ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SHEL Shell Plc

2,858.50
-14.50 (-0.50%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shell Plc LSE:SHEL London Ordinary Share GB00BP6MXD84 ORD EUR0.07
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.50 -0.50% 2,858.50 2,855.50 2,856.50 2,881.50 2,846.00 2,872.00 5,507,824 16:35:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Crude Petroleum & Natural Gs 316.62B 19.36B 2.9802 9.58 185.55B

ADRs End Higher, Shell and Eisai Trade Actively

06/01/2023 10:20pm

Dow Jones News


Shell (LSE:SHEL)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Shell Charts.

By Kathryn Hardison

 

International stocks trading in New York closed higher on Friday.

The S&P/BNY Mellon index of American depositary receipts increased 2.2% to 148.13. The European index increased 2.2% to 142.58, the Asian index rose 2% to 173.46, the Latin American index increased 2.8% to 185.88 and the emerging markets index gained 1.9% to 291.58.

Shell PLC and Eisai Co. were among the companies with ADRs that traded actively.

ADRs of Shell rose 3.2% after the oil giant said it expects its quarterly natural-gas profit was "significantly higher" than in the preceding three months when price swings curbed results in that core business. It also expects to pay around $2 billion more in European Union and U.K. energy-profit levies.

ADRs of Eisai increased 4.1% after the Food and Drug Administration approved lecanemab, a new drug promising to slow Alzheimer's disease created by Eisai and partner Biogen Inc.

ADRs of Alterity Therapeutics fell 5% after the biotechnology company's board of directors approved a 1-for-10 reverse ADS split.

 

Write to Kathryn Hardison at kathryn.hardison@wsj.com

 

(END) Dow Jones Newswires

January 06, 2023 17:05 ET (22:05 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

1 Year Shell Chart

1 Year Shell Chart

1 Month Shell Chart

1 Month Shell Chart

Your Recent History

Delayed Upgrade Clock